Research Investment/Funding

Dear Research Advocate:

The Bureau of Economic Analysis has reclassified research and development costs from an “expense” to an “investment” when calculating GDP. We think Members of Congress should do the same. Common sense tells us R&D is an investment, not an expense; in general conversation we all talk about R&D as an investment, but it isn’€™t accounted for that way on the federal books. The arguments we’€™ve been making are now further bolstered by the BEA’€™s decision. Spread the word!

An excerpt of an op-ed by Dr. Jeffrey Vacirca, chief executive and managing partner of North Shore Hematology/Oncology Associates published in Newsday.

Current FOSEP leaders: Renee Agatsuma, Cyan James, Bish Paul, Abigail G. Schindler, PhD, Corey Snelson, PhD, Christopher Terai. (James and Schindler are the main authors)

The August congressional recess is here! Members of Congress are back home for the month long break. Now’€™s the time to speak up and urge policy makers to make research for health a higher national priority before they return to Capitol Hill and make decisions that will affect the health and prosperity of our nation. Join Research!America’€™s social media congressional recess campaign, Medical Research is at Risk. We Need Cures, Not Cuts!

By Jeffrey Harris, founder and Managing Partner of Harris Search Associates, an IIC members Partners firm where he leads the firm’s Higher Education, Academic Medicine and General Management practices.

Op-ed by The Honorable John Edward Porter, Research!America Chair and former U.S.

Dear Research Advocate:

Op-ed by Abigail Schindler, PhD, postdoctoral fellow at the University of Washington, Department of Psychiatry and Behavioral Sciences and co-leader of the Seattle Forum on Science Ethics and Policy published in The Seattle Times.

We NEED CURES, NOT CUTS

Sequestration’€™s arbitrary, across-the-board budget cuts to defense and non-defense spending have ravaged (and will continue to ravage) our research enterprise. Sequestration and the inability of Congress to pass a budget will dramatically reduce funding for medical research and critical public health functions for years to come. Funding cuts are stopping highly promising research in its tracks, squandering exciting new potential for treatments and cures for millions of Americans who are waiting for them.

By Dai Horiuchi, PhD and Bradley Webb, PhD, co-leaders of the Science Advocacy Subgroup and organizing members of the Science Policy Group at the  University of California, San Francisco (a Research!America member).

Pages

Subscribe to RSS - Research Investment/Funding